Payment overview · 2025
General Payments
$383.55
7 reported records · 4 companies
Healthcare provider profile · identity verified
Miranda Lynn Dunham, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · TROY, NY · NPI 1285839878
Verified facts
What the public records show
CMS Open Payments records show Miranda Lynn Dunham, NP received $383.55 in general payments during 2025 across 7 reported records.
Vanda Pharmaceuticals Inc. accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $151.17 | 39.4% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $125.01 | 32.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $83.87 | 21.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.50 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.55 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $141.66 | 3 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $83.87 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $9.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 65 |
| Sertraline Hcl | Sertraline Hcl | 347 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 61 |
| Trazodone Hcl | Trazodone Hcl | 257 | 75 |
| Eliquis | Apixaban | 232 | 53 |
| Torsemide | Torsemide | 209 | 43 |
| Donepezil Hcl | Donepezil Hcl | 201 | 42 |
| Mirtazapine | Mirtazapine | 194 | 33 |
| Gabapentin | Gabapentin | 191 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 164 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 162 | 30 |
| Omeprazole | Omeprazole | 161 | 37 |
| Famotidine | Famotidine | 152 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 24 |
| Lisinopril | Lisinopril | 127 | 25 |
| Furosemide | Furosemide | 123 | 33 |
| Losartan Potassium | Losartan Potassium | 118 | 31 |
| Memantine Hcl | Memantine Hcl | 111 | 19 |
| Simvastatin | Simvastatin | 96 | 24 |
| Potassium Chloride | Potassium Chloride | 93 | 23 |
| Buspirone Hcl | Buspirone Hcl | 89 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 17 |
| Nystatin | Nystatin | 86 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 12 |
| Carvedilol | Carvedilol | 73 | 13 |
| Lamotrigine | Lamotrigine | 73 | 15 |
| Atenolol | Atenolol | 72 | 12 |
| Spironolactone | Spironolactone | 66 | 15 |
| Cephalexin | Cephalexin | 63 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 16 |
| Olanzapine | Olanzapine | 59 | 14 |
| Latanoprost | Latanoprost | 58 | 14 |
| Valsartan | Valsartan | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 11 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 11 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 17 |
| Lorazepam | Lorazepam | 39 | 12 |
| Metformin Hcl | Metformin Hcl | 39 | 14 |
| Naproxen | Naproxen | 38 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Gemtesa | Vibegron | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Galantamine Er | Galantamine Hbr | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.55 · 7 records | Vanda Pharmaceuticals Inc. | CARVYKTI, FANAPT, INGREZZA, PONVORY, RYBREVANT, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error